Andrew McConaghie

The FDA has indicated that the antibody-drug conjugate looks more promising in a subgroup of EGFR mutated lung cancer patients and AstraZeneca has refiled accordingly.

The UK-based major is set for near double-digit growth in 2024 but has become mired in concerns over a fraud probe in China on its third quarter call.

The Swiss biotech is expanding on its Claudin-1 targeting antibodies in fibrosis by moving into Phase I with its potential first-in-class antibody drug conjugates

Blenrep improved overall survival in the DREAMM-7 study in multiple myeloma patients compared with Darzalex, confirming the antibody-drug conjugate's likely return to the market and potential blockbuster status.

Among the major topics at the conference this week will be the impact on global biopharma of the upcoming Trump administration, frenetic activity in the obesity field, and hopes of increased funding for UK biotech companies.

The FDA said the antibody-drug conjugate looks more promising in a subgroup of EGFR mutated lung cancer patients, which caused AstraZeneca to refile the application.

Incyte is looking to expand in dermatology, but two products at the center of its Escient buyout earlier this year have run into some trouble.

The big pharma will get a first peak at BioAge’s Phase II results for azelaprag, but the biotech is keeping its options open with an ‘incretin-agnostic’ strategy with its exerkine candidate.

Recently recruited from his analyst post, Andrew Baum is now Pfizer's head of strategy and is having to deal with some big decisions on R&D investment and long-term commercial bets.

The US FDA''s Peter Marks told the Jefferies meeting that the agency's scientific leadership will be protected, and said it wants to do more to help the sector accelerate innovation.